What Happened?
Somerville, MA-based Finch Therapeutics Appointed Bryan Gillis as Chief Technology Officer
Date of management change: January 06, 2022
Somerville, MA-based Finch Therapeutics Appointed Bryan Gillis as Chief Technology Officer
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.
Bryan Gillis is Chief Technology Officer at Finch Therapeutics. Previously, Bryan held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Alderman Scott, Goraya Shuja, Manuel Patrick, Raneri Michael, Calvert Chris, Devine Teresa, Pere Daniel, Jones Darrin, Reddy Vijayaraghava, Holder John, Roberts Jeffrey
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.